In summary, this study demonstrated that α-hederin could overcome sEVs-dependent resistance to PTX therapy in NSCLC cells in vivo and in vitro by enriching sEVs in miRNAs targeting TGFβ/SMADs signaling. This evidence concerns the gene TGFB1 and non-small cell lung carcinoma.